Dr. Reddy's marks 25 years on NYSE with closing bell ringing
"We remain unwavering in our purpose: accelerating access to affordable and innovative healthcare, because Good Health Can’t Wait.”
Dr. Reddy's
Dr. Reddy’s to mark 25 years on NYSE with Closing Bell ceremony
“Twenty-five years on the NYSE is more than a listing anniversary; it is a reaffirmation of our commitment to global governance, transparency, and innovation,” Chairman Satish Reddy said.
Dr. Reddy's launches its generic Semaglutide Injection in Canada
Dr. Reddy’s is the first company to receive Health Canada approval for generic Semaglutide Injection in Canada.
Dr. Reddy's announces Health Canada approval for generic Semaglutide Injection in Canada
Dr. Reddy’s becomes the first company to receive marketing authorization for generic Semaglutide Injection in Canada.
Aurigene Pharmaceutical Services and Alveus Therapeutics announce research collaboration
Aurigene provides AI-enabled integrated drug discovery services supporting Alveus’ research programs in obesity and metabolic disease.
Dr. Reddy’s launches first-to-market OTC generic of extra-strength Pataday in U.S.
“The first-to-market launch underscores our capabilities in bringing store-brand equivalents of leading OTC brands to the U.S. market.”
Extrovis AG and Dr. Reddy’s announce the launch of the authorized generic of Carac
Manufactured in Texas at one of Extrovis’ facilities, Dr. Reddy’s Fluorouracil Cream, 0.5%, is indicated for the topical treatment of multiple actinic or solar keratoses of the face and anterior scalp.
Dr. Reddy’s debuts larger size Doan’s
“We are pleased to launch the 100-count — we know back pain affects many adults of all ages,” said Kathryn Healy, head of marketing for Doan’s for manufacturer Dr. Reddy’s.
Q&A: Girotra on Dr. Reddy’s branded O-T-C focus
Girota’s role involves shaping the strategic road map and scaling the business with the aspiration to establish Dr. Reddy’s as a leading player in the consumer health segment
Alvotech and Dr. Reddy’s working to co-develop biosimilar candidate to Keytruda (pembrolizumab)
The collaboration combines Dr. Reddy’s and Alvotech’s proven capabilities in biosimilars, thus, speeding up the development process and extending the global reach for this biosimilar candidate.
Dr. Reddy's named by Science Magazine in top 20 global pharma employers list
This marks the third consecutive appearance of Dr. Reddy’s in the list.